Prognosis
Drug for Ultra Rare Disease Comes with Ultra High Price Tag
- Givlaari’s net price will be $442,000 after discounts included
- Medicine may treat 3,000 porphyria patients in U.S., Europe
Alnylam Pharmaceuticals headquarters in Cambridge, Massachusetts.
Photographer: Kristoffer Tripplaar/Sipa via APThis article is for subscribers only.
Alnylam Pharmaceuticals Inc.’s Givlaari became the first drug to win U.S. approval for patients with an ultra-rare and devastating metabolic disorder. Shares jumped on the news.
It will come with an annual wholesale price tag of $575,000. Patients will need to take it for life.